GlassScriptPhysician profile
Winnie Nhan
NPI 1245681709
$2,414.75
in general payments reported to CMS, 2019-2025
23 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2021: $280 · 2022: $512 · 2023: $554 · 2024: $524 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $577.73 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $347.41 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $313.91 | 2021-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $218.74 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $124.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.54 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $110.84 | 2021-2025 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $90.39 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $81.42 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $68.33 | 2021-2025 | Gvoke Hypopen |
| Insulet Corporation | $64.91 | 2022-2025 | Omnipod |
| Sequel Med Tech, LLC | $47.38 | 2025 | Twiist |
| Abbvie INC. | $46.89 | 2023-2025 | |
| Antares Pharma, INC. | $37.54 | 2023 | Tlando, Xyosted, Nocdurna |
| Pfizer INC. | $26.89 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.52 | 2023 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $19.22 | 2024 | |
| Beta Bionics, INC. | $16.71 | 2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $15.97 | 2022 | |
| Embecta Corp. | $15.78 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amneal Pharmaceuticals LLC | $15.72 | 2024 | Unithroid |
| Theracosbio, LLC | $14.84 | 2024 | Brenzavvy |
| Radius Health, INC. | $14.09 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winnie Nhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.